AbbVie | 8-K: Abbvie to Acquire Immunogen, Including Its Flagship Cancer Therapy Elahere® (Mirvetuximab Soravtansine-Gynx), Expanding Solid Tumor Portfolio
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.